Type 2 Diabetes on the NP Exam: Starting Metformin and Choosing the Second Agent

Type 2 diabetes items on the FNP and AGNP exams test two decisions: how to start metformin safely, and which drug to add when the patient needs more than metformin. Metformin starts at 500 mg twice daily or 850 mg once daily with meals, is not started when eGFR is 30 to 45 mL/min/1.73 m2, and is stopped below 30. The second agent is chosen by comorbidity before glucose: a GLP-1 receptor agonist or SGLT2 inhibitor with proven benefit for ASCVD or high cardiovascular risk, an SGLT2 inhibitor for heart failure, and an SGLT2 inhibitor or GLP-1 receptor agonist for chronic kidney disease, each irrespective of A1c.

The rest of this article follows the order a provider works through in clinic: baseline assessment, metformin initiation, the comorbidity screen that decides the second drug, the glucose-centered choice when no comorbidity applies, insulin triggers, monitoring and the traps a board item uses. Thresholds and recommendations come from the ADA Standards of Care in Diabetes 2026 and the metformin prescribing information.

Baseline assessment before the first prescription

The diagnosis rests on the ADA criteria (A1c 6.5 percent or higher, fasting glucose 126 mg/dL or higher, 2-hour glucose 200 mg/dL or higher on a 75 g OGTT, or a random glucose of 200 mg/dL or higher with classic symptoms), confirmed by a second abnormal result unless hyperglycemia is unequivocal. Before choosing a drug, the provider gathers the data that the treatment algorithm actually uses:

• Cardiovascular status: established ASCVD (prior myocardial infarction, stroke, revascularization, symptomatic peripheral artery disease) or indicators of high risk.
• Heart failure: history, symptoms, and ejection fraction if known.
• Kidney function: eGFR and urine albumin-to-creatinine ratio. The eGFR decides whether metformin can start; albuminuria and eGFR decide the CKD pathway.
• Weight and BMI: obesity makes weight benefit a treatment goal of its own in the 2026 Standards.
• Hypoglycemia risk: age, cognitive status, living alone, driving or hazardous work, erratic meals.
• Liver disease: suspected metabolic dysfunction-associated steatotic liver disease changes the preferred agents.
• Clues that this is not type 2 diabetes: rapid weight loss, ketosis, a lean younger adult or autoimmune history raise the question of type 1 diabetes or latent autoimmune diabetes, which needs insulin and is a referral question, not a metformin question.
• Cost and coverage: the ADA builds cost and access into shared decision-making.

Starting metformin

Metformin lowers hepatic glucose output, carries a low risk of hypoglycemia on its own, is weight neutral to modestly weight reducing and is inexpensive. The labeled immediate-release regimen:

• Start 500 mg twice daily or 850 mg once daily with meals.
• Increase by 500 mg weekly or 850 mg every 2 weeks as tolerated.
• Maximum 2,550 mg a day in divided doses; doses above 2,000 mg may be better tolerated three times daily with meals.

Gastrointestinal effects (diarrhea, nausea, bloating) are the main reason patients stop. Slow titration, dosing with food and an extended-release formulation reduce them.

The kidney rules the exam expects you to apply

The label also directs holding metformin at the time of or before an iodinated contrast study in patients with eGFR 30 to 60, liver disease, alcoholism, heart failure or intra-arterial contrast, with eGFR rechecked 48 hours later before restarting. Metformin is avoided in conditions that predispose to lactic acidosis, such as hypoxic states, sepsis, decompensated heart failure and heavy alcohol use.

Vitamin B12

Long-term metformin lowers vitamin B12 levels. The ADA recommends periodic B12 assessment during long-term therapy, especially in patients with anemia or peripheral neuropathy. A vignette with new numbness in the feet on years of metformin is often testing B12, not only diabetic neuropathy.

When metformin alone is not the opening move

Three ADA 2026 recommendations change the first step:

1. Combination therapy at initiation. The ADA suggests considering combination therapy at the start of treatment to shorten the time to the individualized goal. Earlier editions tied this to an A1c well above goal, commonly 1.5 to 2 percent above target (confirm in the current guideline).
2. Insulin. Consider insulin when there is evidence of ongoing catabolism (weight loss), symptoms of hyperglycemia, an A1c above 10 percent or a glucose of 300 mg/dL or higher.
3. GLP-1 based therapy before insulin. In adults without severe hyperglycemia or a hyperglycemic crisis, GLP-1 based therapy is preferred to insulin for initial or add-on injectable therapy.

Choosing the second agent: comorbidity first

The ADA algorithm asks about organ disease before it asks about glucose. If any of the following is present, the drug is added for protection regardless of A1c and regardless of whether metformin is on board.

When no compelling condition applies

With no cardiorenal disease, the choice turns on how far the A1c is from goal, weight, hypoglycemia risk, side effects, route and cost.

Two rules from the table recur on the exam. First, a DPP-4 inhibitor and a GLP-1 receptor agonist act on the same pathway and are not combined. Second, a sulfonylurea is the wrong add-on for an older adult who lives alone or has had a low, even though it is cheap and lowers A1c effectively.

Starting insulin when it is needed

When insulin is indicated, basal insulin is the usual first step. The ADA insulin figure in recent editions starts basal insulin at 10 units a day or 0.1 to 0.2 units/kg a day and titrates to the fasting glucose goal (confirm the current starting dose and titration schedule in the 2026 figure). If the A1c stays above goal once fasting glucose is controlled, the next step is to add a GLP-1 receptor agonist or prandial insulin rather than push basal insulin indefinitely. Metformin is usually continued alongside insulin when eGFR allows; sulfonylureas are often reduced or stopped once insulin is intensified because the hypoglycemia risk compounds.

Monitoring and follow-up intervals

• A1c: at least twice a year in patients meeting goals, and about every 3 months when not at goal, after a treatment change, or with frequent hypoglycemia or hyperglycemia (ADA Recommendation 6.2).
• Treatment intensification: the ADA states that intensification or deintensification for adults not meeting goals should not be delayed. Clinical inertia is itself a wrong answer.
• Kidney function: eGFR before metformin starts and periodically thereafter, more often as eGFR falls; urine albumin-to-creatinine ratio at least yearly.
• B12: periodically on long-term metformin, sooner with anemia or neuropathy.
• Hypoglycemia: ask at every visit when a patient takes insulin or a sulfonylurea; one or more level 2 or 3 events prompt reevaluation of the regimen.
• Weight and blood pressure: each visit, because both shape the drug choice.

Referral and admission triggers

• Hyperglycemic crisis (diabetic ketoacidosis or hyperosmolar hyperglycemic state), or severe dehydration with altered mental status: emergency evaluation.
• Suspected type 1 diabetes or latent autoimmune diabetes in a patient being treated as type 2: endocrinology.
• Recurrent severe hypoglycemia or hypoglycemia unawareness: endocrinology and a diabetes educator.
• Falling eGFR, rising albuminuria or eGFR below 30: nephrology.
• A1c persistently far above goal despite three or more agents and adherence support: endocrinology.

Patient education the exam expects you to deliver

• Take metformin with meals and expect GI effects to settle over a few weeks; report persistent vomiting or severe diarrhea.
• Hold metformin and SGLT2 inhibitors during acute illness with poor intake, vomiting or dehydration (sick-day rules), and before surgery or contrast as instructed.
• SGLT2 inhibitors: genital hygiene, adequate fluids, and the warning signs of ketoacidosis (nausea, abdominal pain, malaise) even when glucose is near normal.
• GLP-1 receptor agonists: eat smaller meals, stop eating when full, report severe persistent abdominal pain, and report a neck mass or hoarseness.
• Sulfonylureas or insulin: recognize and treat hypoglycemia with 15 to 20 g of glucose, recheck in 15 minutes, and carry a fast-acting source of glucose.
• Lifestyle remains part of every regimen: weight reduction, regular physical activity and a dietary pattern the patient can sustain.

How the exam tests this

• Glucose-first thinking. A vignette with prior myocardial infarction and an A1c of 7.4 percent still needs a GLP-1 receptor agonist or SGLT2 inhibitor with cardiovascular benefit. Options that "intensify metformin" or "recheck in 3 months" are distractors.
• The eGFR window. eGFR 38 in a new patient: metformin is not started. eGFR 38 in a long-term user: reassess, not automatically stop. eGFR 25: stop.
• Wrong add-on for the patient. Sulfonylurea for an older adult with falls, pioglitazone for heart failure, DPP-4 inhibitor plus GLP-1 receptor agonist together.
• Insulin too early or too late. Insulin is correct with weight loss, polyuria and an A1c of 11 percent; it is not the first injectable for an A1c of 8.2 percent without catabolic features.
• Missing the B12 question. New neuropathy and macrocytic anemia on long-term metformin point to B12 deficiency.
• Contrast and surgery. Holding metformin before iodinated contrast in a patient with eGFR 30 to 60 is the expected action.

Practice question

A 61-year-old man with type 2 diabetes returns for follow-up. He had a myocardial infarction 2 years ago and takes metformin 1,000 mg twice daily, atorvastatin, lisinopril, metoprolol and aspirin. He has no symptoms of heart failure. BMI is 33. A1c today is 7.6 percent, unchanged from 3 months ago. eGFR is 74 mL/min/1.73 m2 and the urine albumin-to-creatinine ratio is normal. He has never had hypoglycemia. Which of the following is the most appropriate change to his diabetes regimen?

• A. Add glipizide 5 mg daily
• B. Add sitagliptin 100 mg daily
• C. Add a GLP-1 receptor agonist with proven cardiovascular benefit
• D. Add basal insulin and titrate to a fasting glucose goal

Answer: C. Established ASCVD calls for a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit irrespective of A1c, and his obesity adds a reason to favor weight-reducing therapy. Glipizide (A) lowers A1c but causes weight gain and hypoglycemia and offers no cardiovascular protection. Sitagliptin (B) is weight neutral and well tolerated but has no proven cardiovascular benefit, so it misses the compelling indication. Basal insulin (D) is not indicated without catabolic symptoms, an A1c above 10 percent or glucose of 300 mg/dL or higher, and the ADA prefers GLP-1 based therapy to insulin as the first injectable.

Key points

Related NPPace guides

• Osteoporosis in Primary Care: Who to Screen, Reading the T-Score, FRAX and First-Line Treatment
• Prediabetes: Diagnosis Thresholds, Lifestyle Prescription and When Metformin Is Reasonable
• Thyroid Labs and Levothyroxine Titration: TSH Patterns, Starting Doses and Recheck Timing
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?